Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Biosimilar Goes To FDA, But May Enter Crowded Market

This article was originally published in PharmAsia News

Executive Summary

Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.

You may also be interested in...



Sandoz Neupogen Biosimilar Heads To ODAC; Cmte. May Be Students As Much As Advisors

January meeting date suggests FDA’s review of Sandoz’s abridged filgrastim application is on track, but Oncologic Drugs Advisory Committee could be challenged by differences between biosimilar and conventional BLA development.

Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says

Naming and labeling questions will likely be resolved with agency actions on pending biosimilar applications.

Amgen “Doubling Down” On Innovation As It Sets A Course For The Future

Amgen is planning to launch four new drugs in 2015 while cutting costs by $1.5 billion by 2018, all part of a big push outlined by CEO Robert Bradway Oct. 28 to drive long-term growth as Amgen’s legacy brands come under pressure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC086185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel